drugset / Trial / NCT03986086
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/2
Withdrawn
Nelson Chao
Mereo BioPharma · collabNational Center for Advancing Translational Sciences (NCATS) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is evaluate the safety and tolerability of MPH966, a neutrophil elastase inhibitor, and its ability to prevent graft-versus-host disease after hematopoietic stem cell transplant.
Timeline
- Start
- 2021-09
- Primary completion
- 2022-12
- Completion
- 2023-12
Outcome
Outcome not reported
Stopped (Business): “Lack of Funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alvelestat | Small molecule | 60 mg | Oral |
| Subject | Alvelestat | Small molecule | 120 mg | Oral |
| Subject | Alvelestat | Small molecule | 180 mg | Oral |
| Subject | Alvelestat | Small molecule | 240 mg | Oral |